$0.46
0.04% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US55083R1041
Symbol
LYEL
Sector
Industry

Lyell Immunopharma Inc Stock price

$0.46
-0.24 33.94% 1M
-0.76 61.90% 6M
-0.18 27.38% YTD
-1.63 77.76% 1Y
-4.90 91.33% 3Y
-16.43 97.25% 5Y
-16.43 97.25% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.00 0.04%
ISIN
US55083R1041
Symbol
LYEL
Sector
Industry

Key metrics

Market capitalization $137.22m
Enterprise Value $-174.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.07
EV/Sales (TTM) EV/Sales -2,905.67
P/S ratio (TTM) P/S ratio 2,287.00
P/B ratio (TTM) P/B ratio 0.36
Revenue growth (TTM) Revenue growth -53.08%
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-223.89m
Free Cash Flow (TTM) Free Cash Flow $-162.86m
Cash position $370.53m
EPS (TTM) EPS $-1.31
P/E forward negative
P/S forward 3,166.64
EV/Sales forward negative
Short interest 2.72%
Show more

Is Lyell Immunopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Lyell Immunopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Lyell Immunopharma Inc forecast:

2x Hold
67%
1x Sell
33%

Analyst Opinions

3 Analysts have issued a Lyell Immunopharma Inc forecast:

Hold
67%
Sell
33%

Financial data from Lyell Immunopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.06 0.06
54% 54%
100%
- Direct Costs 20 20
1% 1%
32,717%
-20 -20
0% 0%
-32,617%
- Selling and Administrative Expenses 32 32
31% 31%
54,017%
- Research and Development Expense 152 152
7% 7%
253,800%
-204 -204
12% 12%
-340,433%
- Depreciation and Amortization 20 20
1% 1%
32,717%
EBIT (Operating Income) EBIT -224 -224
11% 11%
-373,152%
Net Profit -343 -343
46% 46%
-571,650%

In millions USD.

Don't miss a Thing! We will send you all news about Lyell Immunopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyell Immunopharma Inc Stock News

Neutral
GlobeNewsWire
25 days ago
SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2024.
Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that members of its senior management team will present and participate the following upcoming investor conferences: H.C.
Neutral
GlobeNewsWire
3 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced pipeline updates, including its plans to advance IMPT-314, a potentially best-in-class therapy for aggressive large B-cell lymphoma, into pivotal trials. IMPT-314 is...
More Lyell Immunopharma Inc News

Company Profile

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Lynn Seely
Employees 300
Founded 2018
Website www.lyell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today